Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer

British Journal of Anaesthesia

Volumn 113, Issue , 2014, Pages i109-i116

  Zylla, D ^a,b,d   Kuskowski, M A ^c   Gupta, K ^a   Gupta, P ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b Hematology Oncology Section   (United States)

^c VA MEDICAL CENTER   (United States)

^d PARK NICOLLET INSTITUTE   (United States)

Author keywords

Analgesics; Metastasis; Morphine; Mortality; Neoplasm recurrence; Opioid; Pain

Indexed keywords

OPIATE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PAIN; CANCER PATIENT; CANCER PROGNOSIS; CHRONIC PAIN; CLINICAL OUTCOME; DISEASE COURSE; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PAIN SEVERITY; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 84985993974     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aeu351     Document Type: Article

References (40)

1. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007; 18: 1437-49
2. Apolone G, Corli O, Caraceni A, et al. Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group. Br J Cancer 2009; 100: 1566-74
3. Barbera LC, Seow H, Husain A, et al. Howoften areopioids prescribed for cancer patients reporting pain? A population-based analysis. J Clin Oncol 2011; 29: abstr 6084
4. Gupta K, Kshirsagar S, Chang L, et al. Morphine stimulates angiogenesis by activating proangiogenic and survival-promotingsignaling and promotes breast tumor growth. Cancer Res 2002; 62: 4491-8
5. Fujioka N, Nguyen J, Chen C, et al. Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer. Anesth Analg 2011; 113: 1353-64
6. Mathew B, Lennon FE, Siegler J, et al. The novel role of the muopioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg 2011; 112: 558-67
7. Farooqui M, Li Y, Rogers T, et al. COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. Br J Cancer 2007; 97: 1523-31
8. Singleton PA, Lingen MW, Fekete MJ, Garcia JG, Moss J. Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation. Microvasc Res 2006; 72: 3-11
9. Farooqui M, Geng ZH, Stephenson EJ, Zaveri N, Yee D, Gupta K. Naloxone acts as an antagonist of estrogen receptor activity in MCF-7 cells. Mol Cancer Ther 2006; 5: 611-20
10. Zagon IS, McLaughlin PJ. Naltrexone modulates tumor response in mice with neuroblastoma. Science 1983; 221: 671-3
11. Chen C, Farooqui M, Gupta K. Morphine stimulates vascular endothelial growth factor-like signaling in mouse retinal endothelial cells. Curr Neurovasc Res 2006; 3: 171-80
12. Lennon FE, Mirzapoiazova T, Mambetsariev B, Salgia R, Moss J, Singleton PA. Overexpression of the muopioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology 2012; 116: 857-67
13. Singleton PA, Moreno-Vinasco L, Sammani S, Wanderling SL, Moss J, Garcia JG. Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation. Am J Respir Cell Mol Biol 2007; 37: 222-31
14. Lennon FE, Mirzapoiazova T, Mambetsariev B, et al. The mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and epithelial mesenchymal transition (EMT) in human lung cancer. PloS One 2014; 9: e91577
15. Nguyen J, Luk K, Vang D, et al. Morphine stimulates cancer progression and mast cell activation and impairs survival in transgenic mice with breast cancer. Br J Anaesth 2014; 113 (SUPPL. 1): i4-13
16. Zylla D, Gourley BL, Vang D, et al. Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Cancer 2013; 119: 4103-10
17. Herndon JE II, Fleishman S, Kornblith AB, Kosty M, Green MR, Holland J. Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma? Cancer 1999; 85: 333-40
18. Efficace F, Bottomley A, Smit EF, et al. Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? Amultivariate analysis of prognostic factors of EORTC study08975. Ann Oncol 2006; 17: 1698-704
19. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormonerefractory prostate cancer. J Clin Oncol 2007; 25: 3965-70
20. Halabi S, Vogelzang NJ, Kornblith AB, et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 2008; 26: 2544-9
21. Quinten C, Coens C, Mauer M, et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 2009; 10: 865-71
22. Halabi S, Lin CY, Kelly WK, et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2014; 32: 671-7
23. Magnon C, Hall SJ, Lin J, et al. Autonomic nerve development contributes to prostate cancer progression. Science 2013; 341: 1236361
24. Garcia-Recio S, Fuster G, Fernandez-Nogueira P, et al. Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer. Cancer Res 2013; 73: 6424-34
25. Boehncke S, Hardt K, Schadendorf D, Henschler R, Boehncke WH, Duthey B. Endogenous mu-opioid peptides modulate immune response towards malignant melanoma. Exp Dermatol 2011; 20: 24-8
26. Iniguez MA, Rodriguez A, Volpert OV, Fresno M, Redondo JM. Cyclooxygenase-2: a therapeutic target in angiogenesis. Trends Mol Med 2003; 9: 73-8
27. Mantyh PW Cancer pain and its impact on diagnosis, survival and quality of life. Nat Rev Neurosci 2006; 7: 797-809
28. WHO. Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. 2012. Available from http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx (accessed February 2014)
29. Madar I, Bencherif B, Lever J, et al. Imaging delta- and mu-opioid receptors by PET in lung carcinoma patients. J Nucl Med 2007; 48: 207-13
30. Singleton PA, Mirzapoiazova T, Hasina R, Salgia R, Moss J. Increased mu-opioid receptor expression in metastatic lung cancer. Br J Anaesth 2014; 113 (SUPPL. 1): i103-8
31. Lissoni P, Meregalli S, Fossati V, et al. Radioendocrine therapy of brain tumors with the long acting opioid antagonist naltrexone in association with radiotherapy. Tumori 1993; 79: 198-201
32. Lillemoe KD, Cameron JL, Kaufman HS, Yeo CJ, Pitt HA, Sauter PK. Chemical splanchnicectomy in patients with unresectable pancreatic cancer. A prospective randomized trial. Ann Surg 1993; 217: 447-55
33. Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 2002; 20: 4040-9
34. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med, Singapore 1994; 23: 129-38
35. Biki B, Mascha E, Moriarty DC, Fitzpatrick JM, Sessler DI, Buggy DJ. Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology 2008; 109: 180-7
36. Christopherson R, James KE, Tableman M, Marshall P, Johnson FE. Long-term survival after colon cancer surgery: a variation associated with choice of anesthesia. Anesth Analg 2008; 107: 325-32
37. Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology 2006; 105: 660-4
38. Gottschalk A, Ford JG, Regelin CC, et al. Association between epidural analgesia and cancer recurrence after colorectal cancer surgery. Anesthesiology 2010; 113: 27-34
39. Cata JP, Keerty V, Keerty D, et al. A retrospective analysis of the effect of intraoperative opioid dose on cancer recurrence after non-small cell lung cancer resection. Cancer Med 2014; 3: 900-8
40. Myles PS, Peyton P, Silbert B, Hunt J, Rigg JR, Sessler DI. Perioperative epidural analgesia for major abdominal surgery for cancer and recurrence-free survival: randomised trial. Br Med J 2011; 342: d1491